Clinical Trials Browser

Phase 1/2 × INDUSTRY × spartalizumab × Clear all

NCT05223231 2026-02-02

Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors

Phase 1/2 Completed

Advanced Malignant Tumors

NCT06265727 2026-01-08

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor, Adult

NCT05941507 2025-09-24

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Phase 1/2 Recruiting

BreastCNSGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Glioblastoma, Head and Neck Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT06425926 2025-08-21

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Phase 1/2 Recruiting

Melanoma

NCT03104699 2025-07-30

A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

Phase 1/2 Completed

211 enrolled 29 charts

Uterine Cervical Neoplasms

NCT06603844 2025-06-03

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT03058289 2025-02-27

IT-01

Phase 1/2 Completed

111 enrolled 21 charts

BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT05662397 2025-02-04

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

Phase 1/2 Active not recruiting

Neoplasms, Recurrence

NCT02325739 2024-10-21

FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression

Phase 1/2 Completed

172 enrolled 33 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04669899 2024-04-09

Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

Phase 1/2 Completed

Neoplasms

NCT02829723 2024-01-18

A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

Phase 1/2 Terminated

192 enrolled 77 charts

Glioblastoma

NCT02608268 2023-12-06

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Phase 1/2 Terminated

252 enrolled 67 charts

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT04193293 2023-09-21

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

Phase 1/2 Terminated

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02795429 2023-07-03

Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC

Phase 1/2 Completed

89 enrolled 37 charts

Gastrointestinal

Liver Neoplasms

NCT02404441 2022-08-03

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Phase 1/2 Completed

319 enrolled 41 charts

BreastDermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT02807844 2021-08-11

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Phase 1/2 Completed

141 enrolled 58 charts

BreastDermatologicGastrointestinalGynecologic

Melanoma, Pancreatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03351231 2020-08-26

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

Phase 1/2 Terminated

7 enrolled 6 charts

Neoplasms